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ABSTRACT

CONTRIBUTION OF ASC-INFLAMMASOME TO VASCULAR ENDOTHELIAL
DYSFUNCTION: ROLE OF RNA RECEPTOR RIG-I

By Ashley L. Pitzer

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2016

Major Director: Pin-Lan Li, MD, PhD, Professor, Pharmacology and Toxicology

Retinoic acid-inducible gene-I (RIG-I) is a putative RNA helicase and recently identified
as a cytosolic RNA receptor in mammalian cells. The role of RIG-I in the regulation of vascular
function under physiological and pathological conditions is unknown. Recent studies have shown
that the inflammasome serves as a crucial initiator of cytokine-mediated inflammation mediating
the pathogenesis of cardiovascular disease. The present study tested whether RIG-I activation
triggers inflammasome formation and subsequent cytokine-mediated inflammation in the
endothelium of mice coronary arteries. Using both genetic and pharmacological interventions of
the RIG-I inflammasome, we first characterized whether specific activation of RIG-I via 3pRNA
transfection induced the formation of an ASC-containing inflammasome in mouse vascular
endothelial cells (MVECs). We confirmed that 3p
RNA dose-dependently increased RIG-I protein levels and release of of type I IFNβ and
IL-1 (a prototype cytokine from inflammasome activation), confirming RIG-I activation. We
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found that MVECs transfected with 3pRNA exhibited increased colocalization of RIG-I with
apoptosis-associated speck-like protein (ASC) or caspase-1 and elevated active caspase-1 and
IL-1β levels, indicating the formation and activation of the RIG-I inflammasome. This RIG-I
inflammasome activation was accompanied by endothelial barrier dysfunction. In the presence of
3pRNA, ZO-1 and ZO-2 and VE-Cadherin expression diminished, and inhibiting caspase-1 and
silencing inflammasome components attenuated this effect. To test the functional role of RIG-I
and its affect on the permeability of mouse ECs, we performed a transwell permeability assay.
Results confirmed that 3pRNA induced increased permeabilization of these mouse ECs, which
was attenuated when inhibiting, and silencing inflammasome components. These data indicate
that increased expression and activity of RIG-I activate IL-1 producing inflammasomes in ECs,
which may represent an early molecular mechanism mediating vascular inflammation and
endothelial dysfunction independent of Nlrp3. Furthermore, we investigated the role of antiaging gene Klotho in the regulation of RIG-I inflammasome activation. The Klotho protein has
been shown to directly interact with RIG-I in senescent cells to block RIG-I multimerization and
downstream production of pro-inflammatory cytokines. Administration of D-saccharic acid 1,4lactone (saccharolactone) in vitro, a pharmacological inhibitor of Klotho activity, substantially
increased inflammasome activation. In addition, mice injected with saccharolactone exhibited
increased RIG-I inflammasome formation and activation. These results suggest that decreased
Klotho activity may activate RIG-I and thereby increase inflammasome activity. Therefore, the
present study defines a novel role for RIG-I inflammasome activation in vascular dysfunction.
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CHAPTER ONE
INTRODUCTION
Chronic inflammation is recognized as a significant contributor to endothelial dysfunction
and damage, which ultimately progresses into cardiovascular disease (CVD), such as
atherosclerosis. The innate immune system has been reported to be an important defense
mechanism within the vasculature in response to exogenous pathogen-associated molecular
patterns (PAMPs) and endogenous damage-associated molecular patterns (DAMPs). The putative
RNA helicase and cytosolic RNA receptor signaling domain, retinoic acid-inducible gene 1 (RIGI), is an essential pathogen recognition receptor (PRR) of the innate immune system in host defense
against viral infections. Double-stranded RNA (dsRNA) produced as a byproduct of viral
replication are recognized by and activate RIG-I, which signals downstream via Mavs
(mitochondrial antiviral signaling protein) to induce type I interferons (IFN) and transcription
factor NF-κB. However, recent studies have also suggested an alternative pathway downstream of
RIG-I activation, independent of Mavs signaling, through apoptosis-associated speck-like protein
(ASC) to induce IL-1β production in human peripheral blood mononuclear cells (PBMCs).
Recently, it has been shown that RIG-I directly interacts with adaptor protein ASC (apoptosisassociated speck-like protein containing a carboxy-terminal CARD) to form an interleukin (IL)1β-producing inflammasome complex 1 2.
The inflammasome is an intracellular multiprotein complex responsible for the action of
inflammation in a variety of tissues or organs. Multiple distinct inflammasomes have previously
been identified and vary based on the PRR sensing domain and stimuli. When the complex is
formed, proteolytic cleavage of pro-caspase-1 results in the bioactive caspase-1. In turn, caspase-

1

1 activation results in the subsequent maturation and secretion of cytokines IL-1β and IL-18 as
well as production of damaging molecules like DAMPs (Martinon et al.,2009) 4 5. Both may turn
on inflammatory response and induce cell dysfunction or injury. Understanding the signaling
mechanism of the RIG-I inflammasome directly within the endothelial cells may reveal the
importance of this inflammasome activation in the development of endothelial dysfunction and
injury associated with vascular inflammation.
1.1 Atherosclerosis
Atherosclerosis has been identified to be the underlying cause of multiple cardiovascular
diseases. By definition, cardiovascular disease is the narrowing of the coronary arteries that supply
blood and transport oxygen to tissues and organs. According to a 2016 report by the American
Heart Association (AHA) in conjunction with the CDC (Center for Disease Control and
Prevention) there are an estimated 86 million American’s who have been diagnosed with one or
more form of cardiovascular disease. CVD continually ranks as the top most prevalent cause of
morbidity and mortality in America. More than half of the population with CVD are reported to
be over the age of 60 6. Many cellular adaptations have been suggested to contribute to the
pathological process of atherosclerosis, including inflammation, hyperlipidemia, reduced nitric
oxide production, and hyperglycemia (Warnatsch et al., 2015)

8 9 10

. Alterations in the vascular

endothelium play a critical role in the development of atherosclerosis 11 and are directly involved
in multiple pathologies such as heart disease, peripheral vascular disease, stroke, and viral
infections. Chronic inflammation has been linked to early-stage endothelial or vascular injury
leading to the development of CVDs. Understanding the early stages of endothelial dysfunction
may provide insight in the early detection and prevention of subclinical atherosclerosis 12.

2

1.1.1 Endothelial Dysfunction in Atherosclerosis
Normally, the endothelium functions to maintain vascular tone and blood flow as well as
to mediate immune function and platelet adhesion. Under normal pathological conditions,
exposure to inflammatory factors are minimal allowing homeostatic conditions. As mentioned
previously, there are multiple risk factors that contribute to alterations within the vascular
endothelium including hypercholesterolemia, hypertension, smoking, aging, as well as
predisposition through family history of atherosclerosis

13 14 15

. In response to such factors, the

vasculature loses its antithrombotic and vasoreactive responses thereby increasing the risk of a
cardiovascular episode if left untreated

16

. Additionally, endothelial dysfunction in response to

various factors may lead to chronic low-grade inflammation, vasoconstriction, vascular lesion and
remodeling, and plaque destabilization (Hadi et al., 2005). Clinical dysfunction of the endothelium
is marked by an imbalance in nitric oxide (NO) production conferring loss of endothelium
dependent vasodilation response. Endothelium-dependent vasodilation can be analyzed by using
many noninvasive techniques to measure coronary endothelial function including phase-contrast
magnetic resonance imaging and Doppler echocardiography 18 19. The Doppler technique implores
acetylcholine and adenosine as a diagnostic tool to measure the vasomotor response 19 of coronary
endothelium.
1.1.2 Inflammation and Atherosclerosis
At the root of many CVD pathogenesis, especially atherosclerosis, is the induction of a
complex and robust inflammatory response. Atherogenesis presents as a chronic inflammatory
disease marked by the presence of immune cells within atherosclerotic lesions

20

. The innate

immune system is involved in the initiation and progression of atherosclerosis through two
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mechanisms: immune cells (macrophages, granulocytes, and monocytes) and humoral components
(PRRs and complement system). Serving as the first line of defense, endothelial cells expressing
PRRs induce secretion of cytokines and chemokines and expression of adhesion molecules to
mediate the migration of immune cells, such as monocytes and T-cells, to the site of injury 21. The
activation of the endothelium in allowing for leukocyte migration into the vascular appears to be
an initiating event towards the progressioin of atherosclerosis. Once in the vasculature, monocytes
differentiate into macrophages, which then act to absorb oxidized low-density lipoproteins (oxLDLs) within the vessel wall. This leads to conversion of the macrophages into foam cells, which
induce a second wave of cytokines. Cytokines released from injurious sites promote the migration
and attachment of additional inflammatory cells to further instigate the inflammatory response 22.
As key components of initiating an inflammatory response, PRRs detect circulating
PAMPs and DAMPs and signal for remediation of the damage. PRRs are comprised of a range of
conserved sensor proteins either bound to the membrane or within the cytosol. These receptors are
grouped into families based on their structure and differential affinity for particular ligands termed
PAMPs. These exogenous PAMPs are characterized by their conserved patterns, which are both
critical for its survival and ability to detect self vs non-self 23. In fact, PRRs also have the ability
to detect endogenous signals of damage that result from localized cellular stress, such as
inflammation and infection 24 25.
It’s been recently suggested that infectious agents may also be significant contributors to
stimulate an inflammatory response that may potentiate atherogenesis (Libby et al., 1997) (Danesh
et al., 1997). This contribution of infection to the development of atherosclerosis and chronic
inflammation may be through both direct and indirect effects

28

. Direct actions of the infectious

agent occur through infection of vasculature cells and surrounding tissue and presence of the agent
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within the atherosclerotic lesion and plaque development. Conversely, an indirect action occurs
when the site of the infection is not within the vasculature but still results in increased cytokine
production leading to atherosclerotic progression (Cambell, 2015). The families of receptors
responsible for detection of infectious agents in the cell include: toll-like receptors (TLRs), the
nucleotide oligomerization domain-like receptors (NLRs), and retinoic acid-inducible gene I (RIGI)-like receptors (RLRs). Among these receptors, the TLRs and NLRs are the best characterized
PRRs. TLRs are comprised of both membrane-bound and cytosolic receptor subtypes

29

, while

NLRs and RLRs are primarily cytosolic receptors (Wells et al.,2011). Cytosolic NLRs have
increasingly become an interesting topic among many investigators due to their ability to recognize
and defend against a vast range of pathogenic factors and their involvement in the formation and
activation of multi-protein complexes called inflammasomes (Lamkanfi & Dixit, 2014) (Man et
al., 2017) (Schroder & Tschopp, 2010) (Takeuchi & Akira, 2010). More recently, RIG-I, a member
of the RLH family, has also been suggested to form an inflammasome complex 1 2.
RIG-I Activation
As a critical innate immune sensor for detecting nucleic acids, specifically viral double
strand (ds) RNA, RIG-I mediates the production of both Type I Interferons (IFNs) and proinflammatory cytokines. Belonging to the RLR family of RNA helicases are the proteins RIG-I,
MDA5, and LGP2. RIG-I consists of two N-terminal caspase activation and recruitment domains
(CARDs), an RNA binding DExD/H-box RNA helicase domain, and C-terminal domain (CTD)
which renders the receptor in an inactive state 34 (Miyashita et al., 2011) 36. This N-terminal CARD
domain is present in the MDA5 receptor; however, the LGP2 lacks this functional group leaving
it without any antiviral properties

37

. The CTD is involved in binding of nucleic acids, and the

CARD domains with ATPase activity are responsible for associating with adaptor proteins and

5

signaling downstream through anti-viral interferon regulator factor (IRF) and pro-inflammatory
NF-B signaling pathways 34. These receptors function to differentiate between self and non-self
RNA within the cytosol to signal for defense against exogenous RNA viruses replicating within
the cell

38

. RIG-I specifically recognizes 5’-ppp-dsRNA with a blunted 5’ cap no longer than

twenty nucleotide base pairs

39 40 41 42

. After ligand binding to the helicase domain, RIG-I

undergoes a conformational change opening up the two CARD domains to signal downstream.
The CARD domains of RIG-I then associate with the mitochondrial adaptor protein MAVS, which
initiates the formation of mitochondrial signaling platform 43 44 45. This RIG-I-MAVS associated
signaling platform is responsible for the activation of transcription factors IRF3 and IRF7, which
in turn initiate synthesis of Type I IFNs

34

. Recently, the CARD domain of RIG-I may also

associate with other adaptor proteins such as CARD9 and BCL-10 for the production of proinflammatory cytokine pro-IL-1 1. This study also determined that activation of the RIG-I during
vesicular stomatitis virus (VSV) infection in peripheral blood mononuclear cells (PBMCs) induced
the formation of an ASC-containing inflammasome 1.
1.2.1 RIG-I Inflammasome
The inflammasome is an intracellular multiprotein machinery responsible for the action of
inflammation in a variety of tissues or organs 46. When the complex is formed, proteolytic cleavage
of pro-caspase-1 results in the bioactive caspase-1. Caspase-1 activation results in the subsequent
maturation and secretion of IL-1 and IL-18 as well as production of damaging molecules like
DAMPs. Production of pro-IL-1 by RIG-I requires activation of caspase-1, and recent evidence
shows that RIG-I triggers the release of IL-1 and IL-18 through caspase-1 and caspase-3
activation after exposure to certain RNA viruses 1 47. In addition, RIG-I has been shown to directly
interact with both inflammasome components caspase-1 and ASC 1 48. The ability of RIG-I to form

6

a protein-protein complex with ASC and caspase-1 suggests the formation of a novel
inflammasome. Poeck et al. determined that this RIG-I inflammasome and its ability to process
proinflammatory cytokines occurs independently of NLRP3 1. Though RIG-I has the ability to
form an inflammasome complex, other RLRs such as MDA5 and LGP2 do not. Selective
activation of MDA5 with dsRNA mimetic poly(I:C) did not result in the activation of caspase-1.
As mentioned previously, RIG-I has been suggested to form a novel inflammasome
complex with ASC and caspase-1. However, there are many publications that suggest that the RIGI-MAVS signaling platform as well as formation of an RIG-I inflammasome may also serve as
priming mechanisms for NLRP3 inflammasome activation 2. In this study, NLRP3 inflammasome
activation in response to infection of human bronchial epithelial cells with the influenza A virus
was dependent on RIG-I priming of pro-inflammatory cytokines in addition to formation of the
RIG-I inflammasome. Additionally, other reports have shown that MAVS plays a role in
translocation of NLRP3 to the mitochondria or priming the NLRP3 inflammasome through cellular
damage 49 50 51

52

. Although RIG-I has the ability to form an inflammasome in response to certain

viral infections, it is unclear whether or not this may play a role in vascular function.
1.2.2 RIG-I in Vascular Inflammation
Maintaining endothelial integrity is a critical component of vascular homeostasis. There is
a growing understanding that endothelial cells may themselves produce inflammatory factors
contributing towards vascular injury. RIG-I is known to facilitate inflammation as an intracellular
virus-sensor. However, accumulating evidence points to a broader function of RIG-I as a mediator
of chronic low-grade inflammation. For instance, RIG-I has been found to be upregulated in
response to DAMPs such as TNF-, LPS, oxidized cholesterol, IL-1, as well as DNA from
damaged senescent cells

53 54 55 56

. Additionally, macrophages in the intima of atherosclerotic
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lesions have also been shown to have an increased expression of RIG-I 57. RIG-I has also been
shown to play a role in T cell activation 58. Specifically, in both endothelial cells and endothelial
progenitor cells, RIG-I activation with synthetic 3pRNA mediated direct endothelial injury
through increased production of reactive oxygen species (ROS). An increase in ROS production
was accompanied with enhanced production of proinflammatory cytokines IL-6 and IL-10 59. Even
though molecular mechanisms mediating the role of RIG-I in inflammatory processes and diseases
is still unclear, it could still become a potential target for proactive treatments of atherosclerosis.
1.2.3 RIG-I and DNA Damage
DNA damage associated with cellular senescence accumulates with ageing and poses as a
risk factor for the development of atherosclerosis. Cellular senescence is defined as the ultimate
fate of the cells and is hallmarked by permanent growth arrest while remaining metabolically
active. A recent study demonstrated that RIG-I can be activated by DNA damage as a result of
cellular senescence. This DNA damage resulted in the release of pro-inflammatory cytokines IL6 and IL-8. They found that addition of exogenous anti-aging protein Klotho blocked RIG-I
multimerization and inhibited its subsequent proinflammatory response 60. Additionally, its been
suggested that induction of the RIG-I/NF-B proinflammatory pathway is due to downregulation
of Klotho associated with age-related inflammation and development of chronic kidney disease
(CKD) 61.

8

1.3 Aims of Study
The present study tested the following hypothesis: specific RIG-I activation leads to
formation and activation of an ASC-containing inflammasome in endothelial cells, thereby causing
endothelial barrier dysfunction and vascular injury.

In order to test this hypothesis, the following specific aims were proposed:
1. To characterize RIG-I-mediated ASC inflammasome formation and activation in
endothelial cells.
2. To test whether this RIG-I-mediated ASC inflammasome formation contributes to
endothelial dysfunction using pharmacological and genetic interventions.
3. To determine the relationship of Klotho activity and RIG-I-mediated inflammasome
formation or activation by inhibiting Klotho activity and expression in endothelial cells.

The overall hypothesis and three specific aims of this project are schematically presented in
Figure 1.

9

Figure 1. The Overall Hypothesis
Through selective activation by 3pRNA both in vivo and in vitro, Aims 1 and 2 will characterize
the activation and formation of RIG-I inflammasome in endothelial cells. More specifically,
these aims will reveal the role of RIG-I inflammasome activation in endothelial barrier
dysfunction. Aim 3 will further elucidate if Klotho may serve as a regulator of RIG-I
inflammasome formation and activation.

10

CHAPTER TWO

GENERAL METHODS

2.1 Mouse Model
Mice with a C57BL/6J background were purchased from Jackson Laboratories (Bar
Harbor, ME). All mice were fed a normal diet (ND) during the treatment times. Mice used for
these treatment groups were eight week old and eight month old wild-type (ASC+/+) and ASC
knockout (ASC-/-) mice. After sacrifice for both mice models, blood samples and heart and aortic
tissues were harvested for biochemical and molecular analysis. All protocols were approved by
the Institutional Animal Care and Use Committee of Virginia Commonwealth University.
2.1.1 In vivo Treatments
For in vivo genetic studies, synthetic ligand 3pRNA or a control double-strand RNA
(CtlRNA) in combination with in vivo-jetPEI (Polyplus, New York, NY), an in vivo polymer based
transfection reagent for delivery of nucleic acids, were injected into the left ventricle of the heart
to carry the lipid-dsRNA transfection mixture to the aorta and surrounding coronary arteries.
Transfection reagent mixture containing CtlRNA was used as a control. A time-dependent study
was used to determine peak effects of 3pRNA for either 3, 7, or 18 days following the initial
injection. After introduction of both 3pRNA and CtlRNA into the circulation, these mice were
maintained on a ND for their respective treatment times.
For in vivo pharmacological studies, ASC+/+ and ASC-/- mice groups received
intraperitoneal (IP) injections of -glucuronidase activity inhibitor, D-Saccharic acid 1,4-lactone

11

(Saccharolactone) (20mg/kg/day) for 7 days while maintained on a ND. The dose for in vivo
injections of saccharolactone were chosen according to a recent study 62 63 64.
2.2 Culture of MVECs
Purchased from ATCC, the mouse vascular endothelial cell (MVEC) line EOMA originally
isolated from mouse hemangioendothelioma was cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco, USA), containing 10% fetal bovine serum (Gibco, USA) and 1% penicillinstreptomycin (Gibco, USA) in a humidified incubator at a mixture at 37°C with 95% air and 5%
CO2. The cells were passaged by trypsinization (Trypsin/EDTA, Sigma), followed by dilution in
DMEM medium containing 10% FBS and 1% penicillin-streptomycin.
2.2.1 In vitro Treatments
To stimulate the RIG-I receptor, the synthetic agonist 3pRNA (Invivogen, San Diego, CA)
and CtlRNA (Invivogen, San Diego, CA) were transfected using the siLentFect Lipid Reagent
(Bio-Rad, CA, USA). The lipid reagent was added to 3pRNA in serum-free medium and incubated
for 25 minutes according to manufacturer’s instruction. After the mixture was added to the cells
and incubated for 6 hours at 37ºC, the medium was replaced with serum-containing medium and
allowed to recovered overnight. Cells were pretreated with pharmacological inhibitors of caspase1 (Ac-YVAD-cmk, YVAD, 5g/mL), HMGB1 (glycyrrhizin, GLYZ, 130 M), and Klotho
(saccharolactone, 10 mM) for 1 hour, 30 min, and 24 hours, respectively.
2.2.2 RNA Interference
MCEVs were transfected with small intereference RNAs (siRNAs) for RIG-I (Santa
Cruz, Santa Cruz, CA), ASC (Qiagen, Germantown, MD), and NLRP3 (Ambion, Austin, TX). In
this study, a scrambled small RNA was used as a control and has been previously confirmed to
be a non-silencing double stranded RNA. For siRNA transfection, siLentFect Lipid Reagent
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(Bio-Rad, CA, USA) was used by incubating in serum-free medium for 25 minutes to allow the
formation of a siRNA-lipid complex. Then, this complex was added to cells and incubated for 6
hours at 37ºC. After incubation, medium was removed and replaced with warmed serumcontaining medium, and cells were incubated overnight for recovery prior to 3pRNA treatment.
2.3 Confocal Microscopy and Immunofluorescence of Cells and Frozen Tissue
Indirect immunofluorescent staining was used to observe the colocalization of
inflammasome proteins and gap junction and adheren proteins. MVECs were cultured in 8-well
chambers and pre-treated with caspase-1, HMGB1, and inflammasome component inhibitors.
After 24 hrs, cells were then fixed in 4% paraformaldehyde in phosphate-buffer saline (PBS) for
15 min. Cells were washed in PBS and primary antibodies incubated overnight at 4°C. The
primary antibodies and concentrations were as followed: mouse anti-RIG-I (1:100, CST,
Beverly, MS), rabbit anti-ASC (1:100, Santa Cruz, Dallas, TX) rabbit anti-caspase-1 (1:200;
Abcam, Cambridge, MA), goat anti-NLRP3 (1:100, Abcam, Cambridge, MA) , rabbit anti-ZO-1
(1:500, Invitrogen, Grand Island, MA), anti-ZO2 (1:500, Invitrogen, Grand Island, NY), and
rabbit anti-VE-Cadherin (1:1000, Abcam, Cambridge, MA). Double immunofluourescent
staining was performed by Alexa Fluor 488 or Alexa Fluor 555-labeled secondary antibody
(1:100, Invitrogen, Grand Island, NY) incubation for 1 hr at room temperature. The samples
were visualized on an Olympus laser scanning confocal microscope (FluoView FV1000;
Olympus, Center Valley, PA, USA) and Image Pro Plus 6.0 software (Media Cybernetics,
Bethesda, MD) were used to analyze colocalization, or degree of overlap between the two
wavelengths, and the colocalization coefficient was represented by Pearson Correlation
Coefficient (PCC) as previously reported 65. The tools in the Image Pro Plus 6.0 software were
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also used to measure immunofluorescence intensity of tight-junction proteins between cell-cell
contact.
2.4 Cellular Protein Homogenates
After recovery, medium of treated MVECs was collected and stored for biochemical and
molecular analysis. Cells were then washed with ice-cold PBS three times and gently scraped down
in ice-cold lysis buffer (Cell Signaling Technology, Beverly, MD) containing protease inhibitor
(Cayman Chemical Company, Ann Arbor, MI). Cellular suspension was transferred into a prechilled microcentrifuge tube and sonicated two times for five minutes each time in an ultrasonic
water bath containing ice. Samples were incubated on ice for 1 hour followed by another 5 minute
sonication, and then centrifuged at 7,000 x g for 8 minutes at 4ºC to remove cellular debris. The
supernatant containing cellular protein was transferred to a new, pre-chilled microcentrifuge tube
and stored at -80ºC until used for Western blot analysis. The Bradford Protein Assay method was
used to determine protein concentrations.
2.5 Western blot analysis
RIG-I expression levels were quantified in cultured MVECs. Protein samples were then
denatured with 5x Laemmli SDS-sample buffer by heating at 95°C for 5 min. Samples with equal
amounts of protein were then loaded onto a prepared 12% SDS-PAGE gel and separated by weight
using electrophoresis at 120V for 1.5 hours. Proteins separated in the gel were then transferred
onto polyvinylidene flouridine (PVDF) membranes (Millipore, Billerica, MA) with a Mini TransBlot® Electrophoretic Transfer Cell (Bio-Rad, Richmond, CA). Membranes were incubated in 5%
fat-free milk prepared in TBS-T for 1 hour at room temperature to block non-specific binding sites.
The PVDF membranes were probed with a primary antibody against anti-RIG-I (1:1000, CST)
overnight at 4°C followed by incubation with horseradish peroxidase-labeled IgG (1:10,000, Santa
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Cruz Biotech). Chemiluminescence was implored to enhance the immunoreactive bands by
exposing the membranes to Super Signal West Pico Substrate Solution (Thermo Scientific,
Rockford, IL), which were then exposed on Kodak (Rochester, New York, USA) X-Ray film and
the protein band density were quantified by densitometry using the ImageJ Software (NIH,
Bethesda, MD).

2.6 RNA Isolation and Real Time Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated from MVECs using TRIzol reagent (Thermo Fisher, Waltham,
MA) according to the manufacturer’s protocol. After washing the cells in 75% ethanol to
precipitate out the DNA and centrifugation, the lower organic pellet containing RNA was
resuspended in RNase-free water. Messenger RNA (mRNA) levels for RIG-I and MDA5 were
analyzed by quantitative reverse transcription using a Bio-Rad iCycler system (Bio Rad, Hercules,
CA) and reverse transcribed to complementary DNA (cDNA) using the iScript cDNA synthesis
kit (Bio Rad). Levels of cDNA were measured and equal amounts for each sample were used to
perform real-time polymerase chain reaction (RT-PCR) using a SYBR supermix kit (Bio Rad).
RT-PCR was ran for 40 cycles at 95 ºC for 15 seconds and 53°C for 45 seconds. PCR efficiency
was examined through serial dilution of template cDNA and PCR specificity with melting curve
data. The mRNA levels of each sample for each gene were normalized to mRNA levels of β-Actin.
2.7 IL-1β, Interferon-β, and HMGB-1 Production
IL-1β (R&D Systems, Minneapolis, MN), interferon-β (R&D Systems, Minneapolis, MN),
and HMGB1 (MyBioSource, San Diego, CA) production were quantified through an ELISA using
tissue culture medium, according to manufacturer’s instructions.
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2.8 Caspase-1 Activity
MVECs

were

labeled

a

fluorescent

FAM-FLICA®

Caspase-1

Assay

Kit

(ImmunoChemistry Technologies, Bloomington, MN). The fluorescent inhibitor probe FAMFLICA-FMK binds the active form of caspase-1. After treatment, cells were incubated with FLICA
and propidium iodide (PI) for 1 hour and washed with PBS. Fluorescence intensity of both FLICA
and PI were analyzed using a Guava EasyCyte flow cytometer (Guava Technologies, Hayward,
CA). Quantification of relative active caspase-1 was represented as the percentage of FLICApositive cells and was normalized to control group for comparison. Caspase-1 activity was also
measured by a commercially available colorimetric assay (Biovision, Mountain View, CA).
2.9 Endothelial Permeability Assay
Endothelial permeability was assessed in vitro using 24-well transwell plates (Corning,
Corning, NY). MVECs were cultured in the 24-well transwell plates and allowed to grow to
confluency. After treatment, the transwell inserts were into non-used well containing fresh serumfree medium. A solution (1mg/ml) of fluorescein isothiocyanate (FITC)-dextran (40kDa) (Sigma,
St. Louis, MO) was then added into each insert and incubated at 37 °C for 1 h to allow passive
diffusion of FITC-dextran molecules to flow from the apical to basolateral side of the endothelial
monolayer. The inserts were removed and the medium from the bottom well was used to determine
fluorescent intensity at excitation/emission of 485/530 nm using a fluorescent microplate reader
(FL X 800, BIO-TEK Instruments). The fluorescence intensity (arbitrary units) was used to
calculate the relative permeability and was normalized to the control group for comparison.
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2.10 Statistics
Data are presented as means ± SEM. Significant differences between and within multiple
groups were examined using one-way ANOVA, followed by Duncan’s multiple-range test. A
Students’ t-test was used to detect significant difference between two groups. The statistical
analysis was performed by SigmaStat 3.5 software. p < 0.05 was considered statistically
significant.
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CHAPTER THREE
RNA receptor RIG-I impairs endothelial barrier function through inflammasome activation
independent of NLRP3
3.1 Rationale and Hypothesis
Recent studies have demonstrated that 3pRNA, a synthetic ligand for the RIG-I receptor,
can activate RIG-I in immune cells such as macrophages and bone marrow derived monocytes,
but the mechanism mediating this 3pRNA-induced formation and activation of RIG-I
inflammasome in endothelial cells remains unknown. As illustrated in Figure 2, the present study
hypothesized that activation of RIG-I through specific agonist 3pRNA triggers ASC-dependent
inflammasome formation, which may be an important initiating mechanism of vascular endothelial
injury. In order to test this hypothesis, we used cultured endothelial cells to characterize the
involvement of RIG-I in inflammasome formation and activation in mediating endothelial
inflammatory responses. Furthermore, we explored a functional role of RIG-I inflammasome
formation and activation as an initiating mechanism to result in endothelial barrier dysfunction,
specifically the severance of paracellular junction proteins.
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Figure 2. Representative schematic illustrating the goals of Aim 1 and 2.
Through selective activation by 3pRNA both in vivo and in vitro, Aims 1 and 2 will explore the
effects of RIG-I inflammasome formation and activation .
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3.2 Results
3.2.1 Characterization of RIG-I expression and activation in MVECs
To investigate the role of RIG-I in MVECs, we tested whether 3pRNA stimulation
increased RIG-I expression and activation. By Western blot analysis with anti-RIG-I antibody,
selective RIG-I activation dose-dependently increased RIG-I protein expression compared to the
CtlRNA group as shown in Figure 3A and summarized in Figure 3B. It has been shown that RIGI activation following viral replication within a cell results in canonical production of Type I
Interferons and pro-inflammatory cytokines. Figure 4A and 4B demonstrate that 3pRNA
stimulation induced release of IFN- and IL-1 in a dose-dependent manner. Furthermore, to
confirm the specificity of 3pRNA in the selective activation of RIG-I rather than other RLRs, we
used RT-PCR to measure changes in mRNA levels of RIG-I and MDA5. Along with RIG-I, MDA5
belongs to the RLR family of RNA receptors; however, while RIG-I recognizes short dsRNA
containing a 5’-triphosphate group, MDA5 has no selectivity for RNA end structures but rather
the length of viral RNA 66 41. Therefore, the triphosphate moiety confers specificity for RIG-I as
opposed to MDA5. We detected a significant increase in mRNA levels of RIG-I; however, levels
of MDA5 significantly decreased (Figure 5A). These data indicate that 3pRNA selectively
activated RIG-I in MVECs and its activation induces release of both pro-viral and proinflammatory cytokines.
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Figure 3. Effect of 3pRNA on RIG-I protein expression.
RIG-I protein expression measured by Western blot in mouse vascular endothelial cells
(MVECs). MVECs were transfected with CtlRNA or 3pRNA in a dose-dependent manner (0.1
g/mL, 0.25 g/mL, and 0.5 g/mL) for 6 h. A. Western blot documents and summarized data
(B) showing the effects of 3pRNA on RIG-I protein expression (n=4). CtlRNA: Control dsRNA,
3pRNA: 5’ppp-dsRNA. * p<0.05 vs. CtlRNA.
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Figure 4. Activation of RIG-I in MVECs by 3pRNA stimulation.
MVECs transfected with CtlRNA and 3pRNA for 6 h dose-dependently (0.1 g/mL, 0.25
g/mL, and 0.5 g/mL) induced production of RIG-I activation markers IFN- (A) (n=6) and
IL-1 (B) (n=6), which were measured in tissue culture medium of transfected cells. CtlRNA:
Control dsRNA, 3pRNA: 5’ppp-dsRNA. * p<0.05 vs. CtlRNA.
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Figure 5. 3pRNA selectively upregulated transcription of RIG-I in MVECs
A. Transfection with 3pRNA (0.5 g/mL) upregulated relative mRNA levels of RIG-I while
simultaneously downregulating MDA5 mRNA levels as quantified using RT-PCR. CtlRNA:
Control dsRNA, 3pRNA: 5’ppp-dsRNA. * p<0.05 vs. CtlRNA.
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3.2.2 3pRNA stimulation induced ASC-dependent inflammasome formation and activation
in vascular endothelial cells
After confirming RIG-I activation in MVECs, we tested whether such activation led to
ASC-dependent inflammasome formation and activation. By confocal microscopy analysis, we
found that induction of RIG-I activation via 3pRNA stimulation exhibited increased colocalization of RIG-I with ASC and RIG-I with caspase-1 (Figure 6), indicated by the increased
yellow puncta. This co-localization suggests that RIG-I assembles with ASC and caspase-1, which
indicates the formation of inflammasomes. However, the same stimulation failed to induce colocalization of NLRP inflammasome markers (NLRP3 with ASC and NLRP3 with caspase-1),
suggesting that 3pRNA-induced RIG-I inflammasome formation occurs independent of NLRP3.
The summarized data is shown in Figures 6B and 4D. Activation of ASC-dependent
inflammasome is associated with both the proteolytic cleavage of pro-caspase-1 to active caspase1 and production of the pro-inflammatory cytokine IL-1. We detected a significant increase in
active caspase-1 indicated by the percentage of FLICA-positive cells, which was quantified using
flow cytometry (Figure 7A). Furthermore, Figure 7B shows a corresponding increase in the
production of IL-1. This 3pRNA-induced inflammasome activation and upregulation of
cytokines were abolished by silencing genes encoding inflammasome components RIG-I and
ASC. Together, these results demonstrate inflammasome formation and activation through specific
activation of RIG-I in vascular endothelial cells.
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Figure 6. 3pRNA transfection increased RIG-I inflammasome formation in mouse
endothelial vascular cells, independent of Nlrp3.
A. Confocal images signifying the colocalization of RIG-I (green) with ASC (red) and RIG-I
(green) with caspase-1 (red). B. Summarized data showing PCC co-localization (n=6). C.
Confocal images analyzing Nlrp3 (green) with ASC (red) and Nlrp3 (green) with caspase-1
(red). D. Summarized data showing failed PCC co-localization (n=6). CtlRNA: Control dsRNA,
3pRNA: 5’ppp-dsRNA. * p<0.05 vs. CtlRNA.
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Figure 7. In vitro induction of RIG-I inflammasome activation in mouse endothelial cells.
A. Caspase-1 activity, shown as percent FLICA positive cells, measured in transfected MVECs
treated with 3pRNA after transfection with genetic inhibitors of the RIG-I inflammasome (n=6).
B. IL-1 production measured in the supernatant of transfected MVECs treated with 3pRNA in
the presence of genetic inhibitors of the RIG-I inflammasome (n=6). CtlRNA: Control dsRNA,
3pRNA: 5’ppp-dsRNA, RIG-Isi: RIG-I siRNA, ASCsi: ASC siRNA. * p<0.05 vs. CtlRNA; #
p<0.05 vs. 3pRNA.
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3.2.3 Global knockout of ASC prevented endothelial RIG-I inflammasome formation and
activation in vivo
By injections of 3pRNA into the circulation via the left ventricle, we tested whether
specific activation of RIG-I in ASC+/+ and ASC-/- mice facilitated inflammasome formation and
activation in vivo. Confocal microscopic analysis demonstrated that 3pRNA increased colocalization of RIG-I with ASC (yellow puncta) or RIG-I with pro-caspase-1 (yellow puncta) in
the vasculature of ASC+/+ compared to CtlRNA treated mice (Figure 8A and Figure 8B).
Furthermore, using von Willebrand factor (vWF) as an endothelial cell marker, we showed that
3pRNA-induced inflammasome formation was mostly located in the vascular endothelium, as
demonstrated by the colocalization of vWF with RIG-I (Figure 8C). Next, we examined whether
endothelial formation of RIG-I inflammasome resulted in production of inflammasome activation
marker, active caspase-1. To test this, active caspase-1 was detected by confocal microscopy using
FLICA, a green fluorescent probe that specifically binds to the active form of caspase-1 protein.
Again, the endothelium was visualized by staining the coronary arteries with vWF. We found that
after 18 days, 3pRNA treatment significantly increased the expression of active caspase-1 (FLICA)
in the endothelium (vWF) as shown by increased co-localization coefficient between FLICA
(green) and vWF (red) (Figure 8D). Together, these data suggest that 3pRNA activate endothelial
RIG-I inflammasomes in coronary arteries in vivo.
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Figure 8. In vivo RIG-I inflammasome formation and activation by 3pRNA stimulation.
A-B. Colocalization of RIG-I (green) with ASC (red) and RIG-I (green) with caspase-1 (red) in
mouse coronary arteries following 3pRNA injections. C. Colocalization of vWF (green) with
RIG-I (red). D. Colocalization of vWF (red) with active caspase-1 fluorescent probe FLICA
(green) (n=3). CtlRNA: Control dsRNA, 3pRNA: 5’ppp-dsRNA. * p<0.05 vs. CtlRNA; #
p<0.05 vs. 3pRNA.
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3.2.4 3pRNA-induced disassembly of tight and adheren junction proteins and
permeabilization in MVECs is dependent on RIG-I inflammasome formation and activation
Recent studies in our lab have demonstrated that activation of NLRP3 inflammasome by
visfatin, a harmful adipokine, induces disruption of inter-endothelial junctions in cultured MVECs.
However, it remains unknown whether RIG-I-mediated inflammasome activation is responsible
for these processes by its selective activation, which are considered as the uncanonical effects of
inflammasome activation. In Figure 9A we demonstrated that after treatment of confluent MVECs
with 3pRNA, fluorescent intensity of junction proteins ZO1 and ZO2 and vascular endothelial
specific adheren protein VE-Cadherin diminished at cell junctions in endothelial monolayers. In
contrast, such 3pRNA-induced disruption of junction proteins was significantly reversed after
inhibition of inflammasome components RIG-I or ASC. However, in cells treated with NLRP3si,
3pRNA remained to have similar effects in the disassembly of junction proteins, suggesting the
lack of NLRP3 involvement in this process. Summarized data for relative fluorescent intensity
(arbitrary units) of each junction protein is shown in Figure 9B. To test the functional role of RIGI inflammasome activation in the endothelium, we used a permeability assay measuring the ability
of dextran conjugated to a fluorescent probe, FITC, and its ability to travel across cell monolayers
67

. Typically, this molecule moves via passive paracellular diffusion and has a low permeability.

Therefore, it is not able to pass across cell monolayers when tight junctions between cells are
maintained. This assay assesses solute leakage which serves as an indicator of physiological
changes in the permeability at intracellular junctions. Figure 9C shows that 3pRNA stimulation
increased permeabilization in endothelial cell layer compared to CtlRNA. Inhibition of
inflammasome components significantly attenuated this paracellular leakage. Additionally,
inhibition of inflammasome activation marker active caspase-1 using Z-YVAD-FMK (YVAD),
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an irreversible caspase-1 inhibitor, significantly attenuated 3pRNA-induced disruption of junction
proteins and blocked permeability at intracellular junctions (Figure 10). Therefore, these results
indicate that formation and subsequent activation of RIG-I inflammasome by 3pRNA causes
disassembly of junction proteins in endothelial cell monolayers and subsequent permeabilization
indicating endothelial damage. This may signify a crucial role of the RIG-I inflammasome
activation in the control of endothelial function as a molecular barrier.
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Figure 9. Endothelial barrier dysfunction associated with RIG-I inflammasome
formation.
Mouse vascular endothelial cells were transfected with either scramble (Scr), RIG-I siRNA
(RIG-Isi), ASC siRNA (ASCsi), or NLRP3 siRNA (NLRP3si) for 6 h and then treated with
CtlRNA or 3pRNA (0.5 g/mL, 6 h). A. Fluorescent staining of tight junction markers, ZO-1
and ZO-2, and endothelial-specific adheren junction marker VE-Cadherin. B. Quantification
of relative intensity (n=5-6). C. Assessment of endothelial permeability where cells were
seeded on transwell inserts, and then stimulated with CtlRNA or 3pRNA for 6 h (n=6).
CtlRNA: Control dsRNA, 3pRNA: 5’ppp-dsRNA.* p<0.05 vs. CtlRNA; # p<0.05 vs. 3pRNA.
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Figure 10. Inhibition of RIG-I inflammasome activation attenuated 3pRNA-induced
endothelial barrier dysfunction.
A. Fluorescent staining of tight junction markers, ZO-1 and ZO-2, and endothelial-specific
adheren junction marker VE-Cadherin in YVAD pretreated MVECs. B. Quantification of
relative fluorescent intensity (n=6). C. Assessment of endothelial permeability where cells were
seeded on transwell inserts, and then stimulated with CtlRNA or 3pRNA for 6 h (n=4). CtlRNA:
Control dsRNA, 3pRNA: 5’ppp-dsRNA, YVAD: caspase-1 inhibitor.* p<0.05 vs. CtlRNA; #
p<0.05 vs. 3pRNA.
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3.2.5 Blockade of HMGB1 activity attenuates RIG-I inflammasome-induced endothelial
damage
Activation of caspase-1 results in both the maturation and secretion of pro-inflammatory
cytokine IL-1 and production of DAMPS such as HMGB1. Both may in turn lead to an
inflammatory response and induce cellular injury or death. Our lab has recently shown an
involvement of the NLRP3 inflammasome in the production of HMGB1 upon visfatin stimulation
and subsequent damage of vascular endothelial monolayer 68. In addition, HMGB1 has been shown
to be released after stimulation by double strand RNA mimetic polyinosinic-polycytidylic acid
(poly I:C). However, the release of HMGB1 and its contribution to RIG-I inflammasome-induced
endothelial barrier dysfunction is unknown. Here, we investigated the role of HMGB1 in 3pRNAinduced RIG-I activation and dysfunction of endothelial cell monolayer integrity. As shown in
Figure 11, 3pRNA treatment increased release of HMGB1 from MVECs into the culture medium,
which was abolished after silencing inflammasome components and inhibiting caspase-1 activity.
Production of HMGB1 was quantified using ELISA (MyBioSource, San Diego, CA). To further
investigate the role of HMGB1 in disruption of cell-cell junctions, confluent endothelial cell
monolayers were treated with 3pRNA in the presence of glycyrrhizin, a HMGB1 activity inhibitor.
Inhibition of HMGB1 activity prevented both 3pRNA-induced disassembly of junction proteins in
the MVEC monolayer (Figure 12A and 12B) and paracellular leakage (Figure 12C). These
results demonstrate that RIG-I inflammasome-dependent HMGB1 release plays a role in 3pRNAinduced disassembly of endothelial tight junctions and increased paracellular leakage of
endothelial monolayers.
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Figure 11. 3pRNA-induced RIG-I inflammasome activation enhanced HMGB1
production.
Effect of 3pRNA treatment on HMGB1 production (A) in MVECs (n=3-6). CtlRNA: Control
dsRNA, 3pRNA: 5’ppp-dsRNA, RIG-Isi: RIG-I siRNA, ASCsi: ASC siRNA, NLRP3si:
NLRP3 siRNA, Vehl: Vehicle-PBS, YVAD: caspase-1 inhibitor, GLYZ: HMGB1 inhibitor. *
p<0.05 vs. CtlRNA; # p<0.05 vs. 3pRNA
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Figure 12. Inhibiting HMGB1 activity attenuated 3pRNA-induced disassembly of junction
proteins and paracellular leakage in MVECs.
MVECs were transfected with CtlRNA or 3pRNA for in the presence of PBS (Vehl: Vehicle)
or HMGB1 inhibitor glycyrrhizin (GLYZ) (130 M) added 1 h prior to transfection. A.
Fluorescent staining of tight junction markers, ZO-1 and ZO-2, and endothelial-specific adheren
junction marker VE-Cadherin. B. Quantification of relative intensity (n=6). C. Assessment of
endothelial permeability where cells were seeded on transwell inserts, and then stimulated with
CtlRNA or 3pRNA for 6 h (n=4). CtlRNA: Control dsRNA, 3pRNA: 5’ppp-dsRNA, Vehl:
Vehicle-PBS, GLYZ: HMGB1 inhibitor. * p<0.05 vs. CtlRNA; # p<0.05 vs. 3pRNA
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3.3 Summary
In summary, we demonstrated in vitro that specific activation of RIG-I by synthetic agonist
3pRNA resulted in the formation and activation of an ASC-dependent inflammasome.
These results signify a novel role of RIG-I inflammasome activation in the control of endothelial
function as a molecular barrier. RIG-I may potentially serve as a therapeutic target in prevention
or treatment of early stages in vascular endothelial damage associated with atherosclerosis.
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CHAPTER FOUR

4.1 Rationale and Hypothesis
We have established that activation of RIG-I initiates the formation and activation of an
ASC-containing inflammasome facilitating endothelial barrier dysfunction. Although Klotho
inhibition has been reported to induce RIG-I activation during cellular senescence and agingrelated inflammation 60, the mechanisms mediating RIG-I inflammasome formation and
activation by Klotho inhibition remains unclear. To this end, we tested the hypothesis that
inhibition of Klotho would result in the activation and formation of the RIG- I inflammasome.
Pharmacological interventions of Klotho activity were administered to assess RIG-I
inflammasome activation in MVECs (Figure 13).
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Figure 13. Representative schematic illustrating the goals of Aim 3.
Aim 3 will establish a relationship between Klotho-associated -glucuronidase activity and
RIG-I inflammasome formation and activation in mouse vascular coronary arteries.
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4.2 Results
4.2.1 Klotho activity inhibition by saccharolactone induced endothelial inflammasome
activation in MVECs
To determine whether targeting Klotho activity can stimulate RIG-I inflamaasome
activation, MVECs were treated with 10 mM saccharolactone, a non-specific inhibitor of glucuronidase activity. As depicted in Figure 14A, treatment of endothelial cells with
saccharolactone resulted in a significant increase in active caspase-1 protein expression in
comparison to untreated cells. Treatment with 3pRNA was used as a positive control for RIG-I
activation in these studies. Summarized data are shown in Figure 14B. Using caspase-1 activity
and production of IL-1 as indicators of inflammasome activation, we found that increased
activation of caspase-1 in saccharolactone treated endothelial cells (Figure 15A). Similarly,
saccharolactone treatment induced elevated production of pro-inflammatory cytokine IL-1
(Figure 15B). In each case, the activation of caspase-1 or production of Il-1 in response to
3pRNA exhibited a greater increase than the saccharolactone treated groups. This may be due to
the non-specific nature of saccharolactone as a -glucuronidase activity inhibitor. These data
suggest a role for Klotho in the induction of inflammasome activation; however, specific
manipulations of Klotho need to be performed in order to confirm these results.
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Figure 14. Effect of Klotho-associated -glucuronidase activity inhibition on proteolytic
cleavage of procaspase-1.
Amelioration of -glucuronidase activity induced proteolytic cleavage of caspase-1 in mouse
vascular endothelial cells (MVECs). MVECs were treated with PBS (Vehl) or saccharolactone
(Sacch.) (10 mM) for 24 h or transfected with CtlRNA (0.5 g/mL) or 3pRNA (0.5 g/mL) for
6 h. A. Representative Western blot documents and summarized data (B) expressed as the ratio
of active caspase-1 versus procaspase-1 (n=3). Vehl: Vehicle-PBS, Sacch.: Saccharolactone,
CtlRNA: Control dsRNA, 3pRNA: 5’ppp-dsRNA. * p<0.05 vs. Vehl; # p<0.05 vs. CtlRNA.
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Figure 15. Inhibition of Klotho-associated -glucuronidase
inflammasome activation in mouse vascular endothelial cells.

activity

enhanced

A. Caspase-1 activity in mouse vascular endothelial cells (MVECs) treated with PBS (Vehl) or
saccharolactone (Sacch.) (10 mM) for 24 h or transfected with CtlRNA (0.5 g/mL) or 3pRNA
(0.5 g/mL) for 6 h. B. IL-1 production in MVECs tissue culture medium after treatment with
PBS (Vehl) or saccharolactone (Sacch.) (10 mM) for 24 h or transfected with CtlRNA (0.5
g/mL) or 3pRNA (0.5 g/mL) for 6 h. (n=3). Vehl: Vehicle-PBS, Sacch.: Saccharolactone,
CtlRNA: Control dsRNA, 3pRNA: 5’ppp-dsRNA. * p<0.05 vs. Vehl; # p<0.05 vs. CtlRNA.
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4.2.2 Mouse ASC gene deletion ameliorated saccharolactone-induced formation and
activation of RIG-I inflammasome in coronary arterial endothelium
To further determine whether targeting Klotho activity initiates activation of the RIG-I
inflammasome formation and activation in vivo, ASC-/- (KO) and ASC+/+ (WT) mice were
administered saccharolactone intraperitoneally and fed a ND for 7 days. The formation of
endothelial RIG-I inflammasome formation was first analyzed by staining coronary arteries with
antibodies against inflammasome components RIG-I and ASC or RIG-I and pro-caspase-1. As
shown in Figure 16, immunofluorescence techniques demonstrated that treatment of mice with
saccharolactone markedly increased formation of RIG-I inflammasome proteins in coronary
arteries of ASC+/+ mice, which is shown by enhanced co-localization (yellow staining). In contrast,
such saccharolactone-induced formation of endothelial RIG-I inflammasome was abolished in
ASC-/- coronary arteries. Furthermore, saccharolactone treatment increased co-localization of RIGI with endothelial marker vWF in both ASC+/+ and ASC-/- mice confirming the activation of RIGI inflammasomes specifically in the endothelium of coronary arteries (Figure 17A). We further
examined whether saccharolactone treatment led to inflammasome activation in the vascular
endothelium by staining the coronary arteries with FLICA, a green fluorescent probe which
specifically binds to the active form of caspase-1, and vWF. Saccharolactone treated ASC+/+
displayed increased inflammasome activation as visualized by yellow staining and co-localization
between FLICA and vWF (Figure 17B). However, this saccharolactone-induced increase in the
co-localization of FLICA with vWF was suppressed in the endothelium layer in coronary arteries
of ASC-/- mice. As shown in Figure 16 and Figure 17A, fluorescent intensity of RIG-I increased
after saccharolactone treatment in both ASC+/+ and ASC-/- mice. This may be attributed to
saccharolactone’s ability to block the activity of Klotho but not expression. Overall, these results
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suggest that RIG-I inflammasome formation and activation is induced in the coronary arterial
endothelium in mice where Klotho activity was inhibited by treatment with saccharolactone.
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Figure 16. Effect of gene knockout or in vivo saccharolactone administration on RIG-I
inflammasome formation.
A-B. Colocalization of RIG-I (green) with ASC (red) and RIG-I (green) with caspase-1 (red) in
mouse coronary arteries following saccharolactone i.p. injections (n=3). Vehl: Vehicle-PBS,
Sacch.: Saccharolactone.* p<0.05 vs. WT-Vehl.
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Figure 17. ASC deficiency prevents saccharolactone-induced RIG-I inflammasome
activation in coronary artery endothelium.
A-B. Colocalization of RIG-I (green) with endothelial marker vWF (red) and active caspase-1
marker FLICA (green) with vWF (red) in mouse coronary arteries of ASC+/+ and ASC-/- mice
treated with i.p. injections of saccharolactone (20 mg/kg/day, 7 days) (n=3). Vehl: VehiclePBS, Sacch.: Saccharolactone. * p<0.05 vs. WT-Vehl.
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4.3 Summary
Taken together, our results demonstrate that blockade of the -glucuronidase activity of
Klotho enhanced the formation and activation of RIG-I inflammasomes in vitro and in vivo.
Additionally, targeting the interaction between Klotho inhibition and activation of the RIG-I
inflammasome occurring directly within the coronary artery endothelium could prevent excessive
inflammatory responses seen in senescence-associated vascular injury.
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CHAPTER FIVE

DISCUSSION

5.1 Selective activation of RIG-I by 3pRNA is sufficient to activate the ASC-containing
inflammasome and induce dysfunction in mice vascular endothelial cells, independent of
NLRP3
The primary goal of this study was to elucidate the involvement of RNA receptor RIG-I in
the formation and activation of ASC-dependent inflammasomes in mice vascular endothelial cells
(MVECs). Our results showed that activation of RIG-I by specific agonist 3pRNA induced RIGI-ASC inflammasome formation and activation in MVECs. Pharmacological interventions and
genetic manipulation of inflammasome components attenuated RIG-I inflammasome formation
and activation in these cells independent of the NLRP3 inflammasome. Results from the present
study demonstrated that inhibiting 3pRNA-induced RIG-I inflammasome activation protected
MVECs against endothelial barrier dysfunction.
The RNA receptor signaling domain, RIG-I, is recognized as an essential constituent of the
immune system. Polymorphisms in the gene encoding RIG-I have been reported to result in
multiple inflammatory and autoimmune diseases such as Singleton-Merten syndrome (SMS),
Systemic Lupus Erythematosus (SLE), and Aicardi-Gourieres syndrome

69 70 71

. The primary

function of RIG-I is the detection of cytosolic viral RNA, and recognizes negative and positive
stranded RNA viruses including vesicular stomatitis virus (VSV), West Nile virus, influenza A
virus, hepatitis C virus, Epstein-Barr virus, and Ebola virus 60 72 73 74 75. After recognition of viral
RNA, specifically 5’ppp double stranded (ds) RNA, conformational change leads to
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multimerization of RIG-I triggering downstream mechanisms inducing production of anti-viral
Type 1 IFNs and pro-inflammatory cytokines 34. The anti-viral functions of RIG-I have been well
defined; however, recent studies have implicated the involvement of RIG-I in inflammatory related
diseases, such as atherosclerosis and aging 61 58 60 59 57. Recently, evidence shows RIG-I associates
with inflammasome adaptor protein ASC and is involved in the activation of IL-1 producing
inflammasomes in immune cells, such as peripheral blood mononuclear cells and macrophages 48
1

. However, the pathophysiological role of the RIG-I inflammasome activation in regulating

endothelial cell functions remains largely unknown. Therefore, we sought to identify whether
activation of RIG-I leads to inflammasome assembly, activation, and subsequent endothelial
dysfunction.
To our knowledge, we are the first to report that activating RIG-I with its specific agonist
3pRNA induces the formation and activation of RIG-I inflammasome in endothelial cells.
Consistently, our results show that treatment with 3pRNA both in vitro and in vivo enhanced the
interactions of inflammasome components RIG-I, ASC, and caspase-1 (Figures 4 and 7).
Consequently, this enhanced association of inflammasome components led to an increased
production of IL-1 in endothelial cells (Figure 6), which was associated with an increase in active
caspase-1 (Figure 5 and 7). Interestingly, the present study found that 3pRNA-induced RIG-I
inflammasome formation occurred independent from NLRP3 (Figure 4).
The inflammasome is a multiprotein complex involved in mediating host defense by
triggering a robust inflammatory response. Recent studies have shown that inflammasome
activation may not only initiate the typical inflammatory response in the vasculature but also
directly induce a series of metabolic and functional disturbances such as activating the production
of damage-associated molecular patterns (DAMPs), impaired endothelium-dependent vasodilation
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(EDVD), and increased endothelial permeability 76 77 78. The endothelium functions as a barrier to
separate luminal blood flow and the rest of the vascular wall through inter-endothelial junctions,
which permit diffusion of molecules less than 3nm in diameter

79

. Inter-endothelial junction

proteins, such as tight junction and adheren junction proteins, regulate the integrity of paracellular
junction permeability 80 81 82. Specifically, a decrease in the expression of tight junction proteins
ZO-1 and ZO-2 and vascular endothelial specific adheren junction protein VE-Cadherin are
hallmark events in mediating inter-endothelial junctional permeability 83

76 84

. Studies in our lab

have demonstrated visfatin-induced NLRP3 inflammasome activation resulted in the severance of
inter-endothelial junction proteins in cultured endothelial cells 76. The results from this study add
to this by showing that RIG-I inflammasome activation resulted in a disruption of endothelial
paracellular junction proteins ZO-1/2 and VE-Cadherin, whereas inhibition of inflammasome
components prevented such 3pRNA-induced downregulation (Figure 8 and 9).
Our data further confirmed that 3pRNA-induced paracellular disruption is primarily
associated with release of high mobility group box 1 (HMGB1). HMGB1 is a major DAMP, which
is released by immune cells during inflammation and infection
release HMGB1 into the extracellular space

86

85

. Necrotic cells also passively

. Once released from the cell, HMGB1 signals

through RAGE receptors and the Src family of tyrosine kinases to induce hyperpermeability 87. In
the present study, we found that inhibition of HMGB1 activity significantly attenuated 3pRNAinduced disassembly of tight and adheren junctions and paracellular leakage in MVECs (Figure
10). These findings are consistent with recent studies demonstrating a role for HMGB1 in
enhanced endothelial barrier dysfunction 87 88

76

. Taken together, our findings support the role for

the activation of RIG-I inflammasome within the endothelium results in severance of interendothelial junction proteins and hyperpermeability.
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5.2 Inhibiting the -glucuronidase activity of Klotho by Saccharolactone enhanced
endothelial RIG-I inflammasome activation
In the present study, we clearly demonstrated that inhibiting the -glucuronidase activity
of Klotho through the administration of saccharolactone resulted in the induction of RIG-I
inflammasome formation, activation of caspase-1, and production of pro-inflammatory cytokine
IL-1 in MVECs. Additionally, we showed that administration of saccharolactone in vivo
enhanced RIG-I inflammasome formation and activation, thus identifying identifying a potential
target in the prevention of excessive inflammatory responses seen in senescence-associated
vascular injury.
Originally identified in 1997 by Kuro-o et al., Klotho has been recognized to be an agingsuppressor gene with many of its functions relating to longevity 89 90 91 92. Deficiency of the antiaging gene Klotho has been associated with many aging phenotypes including atherosclerosis,
osteoporosis, endothelial dysfunction, and cognitive impairment 89 93 94 95. Studies have provided
histological evidence of aortic calcification, medial thickening, and impaired endotheliumdependent vasodilation in homozygous Klotho mice, which closely mirror the pathological
manifestations seen in human arteriosclerosis 95. In addition, senescent cells have been found to
have reduced levels of Klotho, furthering the implication of Klotho in age-related diseases. The
Klotho gene encodes two possible transcripts: a transmembrane form and a secreted form 96 97. The
transmembrane form of Klotho mediates vitamin D balance, phosphate homeostasis, and calcium
handling through its function as co-receptor for fibroblast growth factor 23 (FGF23)

98 91

.

Additionally, the transmembrane form shares sequence homology to family 1 -glycosidases and
has been found to function as a steroid -glucuronidase 99. Acting as a humoral factor, the secreted
form modulates ion channels and transporters, including insulin and insulin-like growth factor-1
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signaling. The transmembrane form of Klotho can be post-translationally cleaved by secretases
resulting in a soluble form. The soluble form regulates nitric oxide production and endothelial
permeability

100 101

. Interestingly, the transmembrane form of Klotho and the secreted form of

Klotho have been shown to attenuate RIG-I-mediated senescence-induced production of proinflammatory cytokines IL-6 and IL-8 through a direct Klotho-RIG-I interaction 60. However, it
remains unknown if and how Klotho may regulate RIG-I inflammasome activation.
It’s been reported that D-saccharic acid 1,4-lactone (saccharolactone) is capable of
inhibiting Klotho-associated -glucuronidase in purified CD4+ T lymphocytes using a flow
cytometry assay to compare the Klotho-associated -glucuronidase activity against total glucuronidase activity 102. Increasing evidence suggests an overlap in the roles of both RIG-I and
Klotho in the pathogenesis of age-related autoimmune diseases such as rheumatoid arthritis (RA).
RIG-I has been found to be highly expressed in synovial tissues from RA patients, which mediated
a pro-inflammatory state and enhanced T cell activation
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. Conversely, lymphocytes of RA

patients showed decreased expression of Klotho and -glucuronidase activity 102. We found that
mice treated with the -glucuronidase inhibitor saccharolactone had enhanced inflammasome
formation (Figure 13) and activation specifically in the coronary artery endothelium (Figure 14).
Saccharolactone treatment enhanced RIG-I fluorescent expression in both ASC+/+ and ASC-/- mice
after treatment with saccharolactone. Since saccharolactone acts to non-selectively inhibit glucuronidase activity, Klotho may still be interacting directly with RIG-I though its activity is
inhibited. In vitro studies confirmed that treatment with saccharolactone led to an upregulation of
inflammasome activation markers caspase-1 and IL-1 production in MVECs (Figure 11 and
Figure 12). Genetic manipulation of Klotho is needed to confirm its role in regulating
inflammasome formation and activation. Taken together, these results suggest a possible role of
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Klotho in mediating RIG-I-dependent inflammasome formation and activation, which may
implicate the RIG-I inflammasome to participate in the inflammatory response of age-related
pathologies.
5.3 Significance and perspectives
There is increasing evidence for an association between vascular endothelial inflammatory
pathologies and RIG-I inflammasome activation, which may result in a low-grade, subclinical
inflammatory state. However, more knowledge and research is needed in this area to further assess
the molecular relationship between RIG-I inflammasome activation and downregulation of Klotho
in age-related inflammatory diseases, in particular, to define the contribution of the activated RIGI inflammasome in the development of endothelial dysfunction and ultimately, atherosclerosis.
Furthermore, understanding the non-canonical effects and alternate pathways of inflammasome
activation may result in cardiac injury independent of an inflammatory state. These direct
damaging effects of inflammasome activation include endothelial permeability, cellular
pyroptosis, and cell-specific protein synthesis interference. Such direct effects of inflammasome
activation may lead to new therapeutic strategies for treatment and prevention of both
inflammatory responses and uncanonical effects associated with progression of cardiovascular
diseases at a time when administration of anti-inflammatory therapeutics have failed. This may
lead to a paradigm shift in the current understanding that inflammation or the inflammasome
complex as being the root to many chronic cardiovascular diseases, including vascular aging.
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